PE20081596A1 - Derivados fluorinados de deferiprona - Google Patents

Derivados fluorinados de deferiprona

Info

Publication number
PE20081596A1
PE20081596A1 PE2008000549A PE2008000549A PE20081596A1 PE 20081596 A1 PE20081596 A1 PE 20081596A1 PE 2008000549 A PE2008000549 A PE 2008000549A PE 2008000549 A PE2008000549 A PE 2008000549A PE 20081596 A1 PE20081596 A1 PE 20081596A1
Authority
PE
Peru
Prior art keywords
iron
ona
alkyl
deferiprone
compounds
Prior art date
Application number
PE2008000549A
Other languages
English (en)
Inventor
Tim Fat Tam
Regis Leung-Toung
Yingsheng Wang
Yanqing Zhao
Original Assignee
Apotex Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotex Technologies Inc filed Critical Apotex Technologies Inc
Publication of PE20081596A1 publication Critical patent/PE20081596A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms

Abstract

SE REFIERE A COMPUESTOS DERIVADOS FLUORINADOS DE DEFERIPRONA DE FORMULA (I) DONDE Y ES NR1, EN DONDE R1 ES H, ALQUILO(C1-C6), CICLOPROPILMETILO, ALILO O CICLOPROPILO; R2 ES H, ALQUILO(C1-C4) O R5CHOH, EN DONDE R5 ES H, ALQUILO(C1-C3) O TRIFLUOROMETILO; R3 ES METILO, H O CF3CHOH; R4 ES CHF2. SON COMPUESTOS PREFERIDOS: 2-DIFLUOROMETIL-5-HIDROXI-PIRAN-4-ONA, 2-DIFLUOROMETIL-5-HIDROXI-1-METIL-1H-PIRIDIN-4-ONA, 1-CICLOPROPIL-2-DIFLUOROMETIL-5-HIDROXI-1H-PIRIDIN- 4-ONA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON QUELANTES DE HIERRO UTILES EN EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS CAUSADAS POR LA PRESENCIA DE HIERRO LIBRE O ACUMULACION DE HIERRO EN TEJIDOS NEURONALES Y EN ENFERMEDADES DONDE EL EXCESO DE HIERRO DEBE SER REMOVIDO O REDISTRIBUIDO
PE2008000549A 2007-03-28 2008-03-27 Derivados fluorinados de deferiprona PE20081596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90729007P 2007-03-28 2007-03-28

Publications (1)

Publication Number Publication Date
PE20081596A1 true PE20081596A1 (es) 2009-02-05

Family

ID=39743019

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000549A PE20081596A1 (es) 2007-03-28 2008-03-27 Derivados fluorinados de deferiprona

Country Status (15)

Country Link
US (2) US8026261B2 (es)
EP (1) EP2134688B1 (es)
CN (2) CN101679263B (es)
AR (1) AR065880A1 (es)
AU (1) AU2008232262B2 (es)
CA (2) CA2627529A1 (es)
CL (1) CL2008000887A1 (es)
IL (1) IL201189A (es)
MX (1) MX2009010407A (es)
NZ (2) NZ600874A (es)
PE (1) PE20081596A1 (es)
TW (1) TWI404533B (es)
UY (1) UY30986A1 (es)
WO (1) WO2008116301A1 (es)
ZA (1) ZA200906712B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081596A1 (es) 2007-03-28 2009-02-05 Apotex Technologies Inc Derivados fluorinados de deferiprona
GB0803019D0 (en) * 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds
CA2722393A1 (en) * 2008-04-25 2009-10-29 Apotex Technologies Inc. Liquid formulation for deferiprone with palatable taste
EA020976B1 (ru) 2009-07-03 2015-03-31 Апотекс Текнолоджиз Инк. Фторированные производные 3-гидроксипиридин-4-онов и способы их использования
JP5777725B2 (ja) 2010-11-29 2015-09-09 ファイザー・インク モノバクタム
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
CN102861017A (zh) * 2011-07-08 2013-01-09 辽宁省计划生育科学研究院 一种化合物在防治老年痴呆的应用
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
JP6169492B2 (ja) 2011-11-15 2017-07-26 武田薬品工業株式会社 ジヒドロキシ芳香族へテロ環化合物
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
WO2015001572A2 (en) * 2013-07-04 2015-01-08 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
US10802459B2 (en) 2015-04-27 2020-10-13 Ademco Inc. Geo-fencing with advanced intelligent recovery
US10516965B2 (en) 2015-11-11 2019-12-24 Ademco Inc. HVAC control using geofencing
US10605472B2 (en) 2016-02-19 2020-03-31 Ademco Inc. Multiple adaptive geo-fences for a building
WO2017152237A1 (en) * 2016-03-10 2017-09-14 The University Of Sydney Novel analogues of desferrioxamine b (dfob)
CN111170936B (zh) * 2020-01-19 2021-01-01 杭州泽德医药科技有限公司 3,4-二羟基-n-(1’-苄基-2’-羟乙基)-2-甲基吡啶氯化物及制备和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918402A (en) * 1958-07-29 1959-12-22 Dodge Chem Co Bactericidal-fungicidal compositions
NL300788A (es) * 1962-12-20
CA1095921A (en) * 1976-08-02 1981-02-17 Thomas M. Brennan Preparation of gamma-pyrones
GB8308054D0 (en) 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
GB8308055D0 (en) 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
GB8325496D0 (en) 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
USRE34313E (en) * 1983-09-23 1993-07-13 National Research Development Corporation Pharmaceutical compositions
GB8329043D0 (en) * 1983-10-31 1983-11-30 Hider R C Pharmaceutical compositions
JPH01305081A (ja) 1988-04-04 1989-12-08 E R Squibb & Sons Inc ３―アシルアミノ―１―［［［（置換スルホニル）アミノ〕カルボニル〕アミノ〕―２―アゼチジノン類
DE3826846A1 (de) * 1988-08-06 1990-02-08 Goedecke Ag Alkoxy-4(1h)-pyridon-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
JPH0714872B2 (ja) 1990-02-06 1995-02-22 昭和薬品化工株式会社 シロップ剤組成物
GB9100465D0 (en) * 1991-01-09 1991-02-20 Hider Robert C Pharmaceutical compositions
US5624807A (en) 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
CA2121435C (en) 1993-04-16 2002-01-22 Sheila M. Ratnaraj Aqueous pharmaceutical suspension and process for preparation thereof
WO1995020584A1 (en) * 1994-01-31 1995-08-03 Pfizer Inc. Method of synthesizing gamma pyrones
JP2001508755A (ja) 1994-04-08 2001-07-03 ザ、プロクター、エンド、ギャンブル、カンパニー 哺乳動物でラジカルダメージを減少させるために鉄キレート化合物を用いる方法
WO1996003976A1 (en) 1994-08-01 1996-02-15 Kv Pharmaceutical Corporation Tastemasked liquid pharmaceutical delivery system
US5616621A (en) 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
JPH0925234A (ja) * 1995-07-12 1997-01-28 Wakunaga Pharmaceut Co Ltd 脳疾患改善剤
US5763449A (en) 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
GB9711093D0 (en) * 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
WO2000012135A1 (fr) 1998-08-28 2000-03-09 Eisai Co., Ltd Compositions medicales presentant une amertume, etc., reduite
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6133322A (en) 1998-10-29 2000-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6933104B1 (en) 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
IL130324A0 (en) * 1999-06-07 2000-06-01 Yeda Res & Dev Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators
AUPQ262499A0 (en) 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
CA2313270C (en) 2000-06-30 2011-09-13 Apotex Inc. Use of deferiprone in treating and preventing iron-induced cardiac disease
US6806256B2 (en) 2001-03-05 2004-10-19 Ortho -Mcneil Pharmaceutical, Inc. Taste masked liquid pharmaceutical compositions
AU2003222513A1 (en) 2002-03-08 2003-09-22 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
WO2003077842A2 (en) 2002-03-12 2003-09-25 Bristol-Myers Squibb Company Palatable oral suspension and method
WO2004006856A2 (en) * 2002-07-12 2004-01-22 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression
AU2003282337B2 (en) 2002-11-07 2009-07-16 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
DE10336497B4 (de) * 2003-08-08 2007-04-05 Freie Universität Berlin Substituierte Pyridine und ein Verfahren zur Herstellung von substituierten Pyridinen
EP1742535A4 (en) 2004-05-06 2008-10-15 Cydex Pharmaceuticals Inc MASTER TASTE PREPARATIONS CONTAINING SERTRALINE AND SULFOALKYLETHER CYCLODEXTRIN
US9737511B2 (en) 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
WO2005115379A2 (en) 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US7728038B2 (en) 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
JP2006150061A (ja) 2004-11-04 2006-06-15 Nec Corp ドラッグデリバリシステム及びそれに用いる薬剤カプセル並びに送信機
US20070197469A1 (en) 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
JP5730466B2 (ja) 2006-02-22 2015-06-10 アポテックス テクノロジーズ インク．Ａｐｏｔｅｘ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． 鉄の細胞内不良処理からもたらされるフリードライヒ運動失調症の治療及び／又は予防のための方法およびデフェリプロンの使用
PE20081596A1 (es) 2007-03-28 2009-02-05 Apotex Technologies Inc Derivados fluorinados de deferiprona
GB0803019D0 (en) 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds

Also Published As

Publication number Publication date
US20080242706A1 (en) 2008-10-02
TWI404533B (zh) 2013-08-11
UY30986A1 (es) 2008-09-02
ZA200906712B (en) 2011-02-23
US8673943B2 (en) 2014-03-18
EP2134688B1 (en) 2016-10-05
MX2009010407A (es) 2009-12-01
CN102964296A (zh) 2013-03-13
CN101679263B (zh) 2014-01-15
WO2008116301A1 (en) 2008-10-02
US8026261B2 (en) 2011-09-27
AU2008232262B2 (en) 2013-02-14
TW200843760A (en) 2008-11-16
EP2134688A4 (en) 2011-01-19
AU2008232262A1 (en) 2008-10-02
CN102964296B (zh) 2015-03-25
CL2008000887A1 (es) 2008-05-30
CA2681545A1 (en) 2008-10-02
AR065880A1 (es) 2009-07-08
CA2627529A1 (en) 2008-09-28
US20120095061A1 (en) 2012-04-19
IL201189A0 (en) 2010-05-17
NZ600874A (en) 2013-01-25
NZ579928A (en) 2012-09-28
IL201189A (en) 2015-06-30
CA2681545C (en) 2013-10-01
CN101679263A (zh) 2010-03-24
EP2134688A1 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
PE20081596A1 (es) Derivados fluorinados de deferiprona
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
MX2011012628A (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
MX2009008338A (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
MA32903B1 (fr) Inhibiteurs de proteine-kinases
CY1110014T1 (el) Παραγωγα τετραϋδροκαρβαζολιου χρησιμα ως τροποποιητες υποδοχεα ανδρογονων (sarm)
PE20090695A1 (es) Derivados de pirimidindiona como agonistas del receptor de acido nicotinico
PE20140918A1 (es) Compuestos de benzoxepina inhibidores de la pi3k
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
TW200639159A (en) Treatment of pain
MA32563B1 (fr) Dabigatran pour cathétérisme cardiaque de chirurgie percutanée
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
WO2009137251A3 (en) Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
EA201171339A1 (ru) Способ снижения внутриглазного давления у людей
PE20091092A1 (es) Compuestos heterociclicos como inhibidores de la via hedgehog
IN2012DN02502A (es)
PE20142421A1 (es) Fenilimidazopirazoles sustituidos y su uso

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed